ACADIA Pharmaceuticals Inc. (ACAD)
ACAD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$18.62
-4.07% on the day
Market cap
$3.2B
Mid cap
Revenue · 2025
$1.1B
+11.9% on 2024
Net income · 2025
$391.0M
36.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ACAD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 1985 |
| SEC CIK | 0001070494 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.1B |
| Net income | $391.0M |
| Operating income | $104.8M |
| Net margin | 36.5% |
| Operating margin | 9.8% |
| Revenue growth | +11.9% |
| Cash | $177.7M |
| Total assets | $1.6B |
| P/E (computed) | 8.2× |
| P/S (computed) | 3.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2025-05-09 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-09-24 |
| Latest proxy | DEF 14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.0% |
| 1 month | -28.1% |
| 3 months | -24.9% |
| Year to date | -27.9% |
| 1 year | -4.0% |
| From 52-week high | -37.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PBLS | Parabilis Medicines Inc. | $26.85 | -7.25% | $3.3B |
| ARQT | Arcutis Biotherapeutics Inc. | $26.09 | -0.50% | $3.3B |
| IDYA | IDEAYA Biosciences Inc. | $34.26 | -4.99% | $3.3B |
| XENE | Xenon Pharmaceuticals Inc. Common Shares | $34.42 | -3.88% | $3.3B |
| VKTX | Viking Therapeutics Inc. | $26.65 | -5.96% | $3.3B |
| AMLX | Amylyx Pharmaceuticals Inc. | $26.85 | -2.29% | $3.4B |
| LEGN | Legend Biotech Corporation | $17.88 | +0.45% | $3.5B |
| ELVN | Enliven Therapeutics Inc. | $39.49 | -3.31% | $2.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier